Device Trial Radar · NCT01757444
Non Invasive Ventilation : Efficacy of a New Ventilatory Mode in Patients With OHS
Last checked: Nov 19, 2026Latest source record: Sep 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Jun 2013
Primary completion
Sep 2018
Study completion Sep 2018
Sponsor
- Lead sponsor
- Association Nationale pour les Traitements A Domicile, les Innovations et la RechercheAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 31, 2012
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In 2012, it has announced the availability of the new ventilator (BiPAP- A40), which could offer potential advantages over fixed level pressure support, in particular, in patients with obesity hypoventilation syndrome (OHS). One of the key benefits of the BiPAP A40 is an innovative ventilation mode called AVAPS-AE, which automatically maintains airway patency while delivering the correct level of ventilation each user requires, whatever their body position or sleep stage. AVAPS-AE mode is also aimed to help the clinicians during the initial titration of therapy, while providing long term comfort and assuring therapy compliance. However, studies on the physiologic and clinical effects have not yet been performed. The aim of our singled-blind randomised multicentre controlled trial is to prospectively investigate the effects of BiPAP with the spontaneous/timed (S/T) or the AVAPS-AE ventilation mode over 8 weeks on sleep quality, ventilation pattern, gas exchange, symptoms, body composition, level of physical activity and health-related quality of life in OHS patients.
Conditions
- Obesity Hypoventilation Syndrome
Interventions
BiPAP - A40Device
Patients receiving BiPAP AVAPS - AE ventilatory mode at home
BiPAP - STDevice
Patients receiving BiPAP- ST mode at home.
Primary outcomes
What the sponsor says the trial is designed to measure.
- CHANGE IN SLEEP QUALITYTime frame: Day 1 and Day 61
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Centre Hospitalier Universitaire d'Angers
Angers, France
Centre Hospitalier de Béziers
Béziers, France
Hôpital Haut- Lévêque
Bordeaux, France
8 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.